Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
09/2007
09/26/2007EP1836165A1 Dipyrrole compounds, compositions, and methods for treating cancer or viral diseases
09/26/2007EP1836164A1 11c-labeled benzyl-lactam compounds and their use as imaging agents
09/26/2007EP1836163A2 Pyrrolidine derivatives for the treatment of a disease depending on the activity of renin
09/26/2007EP1836162A2 Antibacterial agents
09/26/2007EP1836160A1 Compounds for treating metabolic syndrome
09/26/2007EP1836156A1 Substantially pure tolterodine tartrate and process for preparing thereof
09/26/2007EP1836154A1 Polymorphs of memantine hydrochloride
09/26/2007EP1836153A2 Reducing carbohydrate derivatives of adamantane amines, and synthesis and methods of use thereof
09/26/2007EP1836151A2 Vitamin d receptor modulators
09/26/2007EP1835936A2 Compositions and methods for regulating apoptosis
09/26/2007EP1835934A2 Enzyme modulators and treatments
09/26/2007EP1835923A2 Regimens for intra-articular viscosupplementation
09/26/2007EP1835922A1 Combination treatment for multiple sclerosis
09/26/2007EP1835921A2 9a-carbamoyl-y-aminopropyl- and 9a-thiocarbamoyl-y-aminopropyl-azalides with antimalarial activity
09/26/2007EP1835920A1 Drugs for the treatment and/or prophylaxis of gastroparesis symptom
09/26/2007EP1835919A1 Dry eye treatment
09/26/2007EP1835918A2 Inhibitors of checkpoint kinases
09/26/2007EP1835917A1 Agents containing folic acid, vitamin b6 and vitamin b12, and the use thereof
09/26/2007EP1835916A1 Compounds useful in the treatment of hiv
09/26/2007EP1835915A2 Immune response modifier formulations and methods
09/26/2007EP1835914A1 Sabcomeline alone or combined with a mood stabilising or antimanic agent to treat bipolar disorders
09/26/2007EP1835913A2 Ibudilast for treating neuropathic pain and associated syndromes
09/26/2007EP1835912A1 Substituted benzimidazoles for treatment of histomoniasis
09/26/2007EP1835911A2 Therapeutic compositions for intranasal administration of ketorolac
09/26/2007EP1835910A2 Methods of using [3.2.0] heterocyclic compounds and analogs thereof
09/26/2007EP1835909A2 Biomarkers for identifying efficacy of tegaserod in patients with chronic constipation
09/26/2007EP1835908A2 Indole derivatives with antitumor activity
09/26/2007EP1835907A1 Medicaments for the treatment or prevention of fibrotic diseases
09/26/2007EP1835906A1 Injectable or orally deliverable formulations of azetidine derivatives
09/26/2007EP1835905A2 Use of selected compounds for protection of neurones and oligodendrocytes in the treatment of multiple sclerosis
09/26/2007EP1835904A1 Composition for stimulating growth of dermal papilla cells and promoting hair follicle growth comprising vitamin c derivatives
09/26/2007EP1835903A1 Complex formulation of 3-hydroxy-3-methyl glutaryl coa reductase inhibitor and antihypertensive agent, and process for preparing same
09/26/2007EP1835902A2 Spiro[bornyl-2,4'-(1,3-dioxanes)] and their uses as fragrance ingredients
09/26/2007EP1835901A2 Treatment with omega-3 fatty acids and ppar agonist and/or antagonist and a combination product thereof
09/26/2007EP1835900A1 Sulfasalazine analogues as nf-kb inhibitors
09/26/2007EP1835899A1 Treatment of hcv disorders
09/26/2007EP1835898A2 Methods for modulating tumor growth and metastasis
09/26/2007EP1835897A2 Oxygen-impervious packaging with optional oxygen scavenger, stabilized thyroid hormone compositions and methods for storing thyroid hormone pharmaceutical compositions
09/26/2007EP1835896A2 Use of certain phenyl napthyl compounds for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis (ms)
09/26/2007EP1835895A2 Use of certain phenyl-naphthyl compounds that do not have significant affintiy to er alpha or beta for protection of neurons and oligodendrocytes in the treatment of multiple sclerosis
09/26/2007EP1835893A1 Pharmaceutical composition containing coated, floating particles
09/26/2007EP1835890A2 Nanoparticulate candesartan formulations
09/26/2007EP1835888A1 Cholanic acid-chitosan complex forming self-aggregates and preparation method thereof
09/26/2007EP1835819A1 Sachets comprising plant sterol
09/26/2007EP1753461B1 Stabilized compositions comprising a therapeutically active agent, citric acid or a conjugated base and chlorine dioxide
09/26/2007EP1742902B1 Hexenoic acid derivatives, processes for the preparation thereof, pharmaceutical compositions comprising them, and therapeutic applications thereof
09/26/2007EP1725211B1 Peeling cosmetic method using a 8-hexadecene-1,16-dicarboxylic acid
09/26/2007EP1687293B1 Indazol-3-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1)
09/26/2007EP1656354B1 Tetrahydroquinazoline derivatives as cfr antagonists
09/26/2007EP1653948B1 Use of 5-methoxytryptamine as a cardioprotective agent
09/26/2007EP1651234B1 Combination of mglur2 antagonist and ache inhibitor for treatment of acute and/or chronic neurological disorders
09/26/2007EP1622577A4 Prevention of deficits in neurogenesis with anti-inflammatory agents
09/26/2007EP1559715B1 N-{2-chloro-4-[(6,7-dimethoxy-4-quinolyl)oxy]phenyl}-n'-(5-methyl-3-isoxazolyl)urea salt in crystalline form
09/26/2007EP1554298A4 Process for the preparation of 9-beta-anomeric nucleoside analogs
09/26/2007EP1554250B1 Novel lactams and uses thereof
09/26/2007EP1539755B1 6-alkoxy-pyrido-pyrimidines as p-38 map kinase inhibitors
09/26/2007EP1539203B1 Echinacea angustifolia extracts
09/26/2007EP1532981B1 Stable eye drops containing latanoprost as the active ingredient
09/26/2007EP1501485B1 High drug load tablet
09/26/2007EP1490364B1 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders
09/26/2007EP1474416B1 Dihydrobenzodiazepin-2-one-derivatives for the treatment of neurological disorders
09/26/2007EP1458708B1 Heteroaryl substituted triazole modulators of metabotropic glutamate receptor-5
09/26/2007EP1451153B1 Nk1 antagonists
09/26/2007EP1438040B1 Pharmaceutical compositions comprising mycophenolic acid or mycophenolate salt
09/26/2007EP1418908B1 Compounds for eliminating and/or relieving anhedonia
09/26/2007EP1417173B1 Substituted 2-thio-3, 5-dicyano-4-phenyl-6-aminopyridines and their use as adenosine receptor-selective ligands
09/26/2007EP1414825B1 Thienopyrimidinediones and their use in the modulation of autoimmune disease
09/26/2007EP1411951B1 Enteral compositions for the prevention and/or treatment of sepsis
09/26/2007EP1409740B1 Asthma-associated gene
09/26/2007EP1408948B1 Thyroid therapeutic agent comprising partial glycerides and dextrine
09/26/2007EP1406873B1 Fluoropyrrolidines as dipeptidyl peptidase inhibitors
09/26/2007EP1399141B1 Use of acetyl l-carnitine for the preparation of a medication for the preventive therapy of post-surgical pain
09/26/2007EP1383750B1 Urea derivatives as integrin alpha 4 antagonists
09/26/2007EP1374871B1 Crystalline isoxazole derivative and medical preparation thereof
09/26/2007EP1358181B1 Substituted pyrrolidines as ccr-3 receptor antagonists
09/26/2007EP1353645B1 Method for the production and use of a cream containing vitamin-a.
09/26/2007EP1341777B1 1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
09/26/2007EP1341753B1 Cyclohexyl(alkyl)-propanolamines, preparation method and pharmaceutical compositions containing same
09/26/2007EP1339678B1 Ep4 receptor selective agonists in the treatment of osteoporosis
09/26/2007EP1322673B1 Polysaccharides with antithrombotic activity comprising at least a covalent bond with biotin or a biotin derivative
09/26/2007EP1313481B1 Pharmaceutical composition comprising condensed indole compound
09/26/2007EP1307187B1 Use of 13-cis retinoic acid for the treatment of emphysema
09/26/2007EP1303520B1 Therapeutic compounds and methods
09/26/2007EP1302461B1 Tnf-alpha production inhibitors
09/26/2007EP1276732B1 Amides of r-2-(aminoaryl)-propionic acids for use in theprevention of leucocyte activation"
09/26/2007EP1268416B1 2-alkylidene-19-nor-vitamin d compounds and their therapeutic uses
09/26/2007EP1265596B1 Medical emulsion for lubrication and delivery of drugs
09/26/2007EP1263726B1 N-acylpyrrolidin-2-ylalkylbenzamidine derivatives as inhibitors of factor xa
09/26/2007EP1261585B1 Substituted indole mannich bases
09/26/2007EP1228367B1 Aminophenoxyacetamide derivatives and pharmaceutical composition containing thereof
09/26/2007EP1228046B1 Phthalazinone derivatives as pde 4 inhibitors
09/26/2007EP1198239B1 METHODS EMPLOYING BACTERIAL ParD kis/ParD kid TOXIN-ANTITOXIN SYSTEM FOR KILLING EUKARYOTIC CELLS
09/26/2007EP1194447B1 Novel potassium channels and genes encoding these potassium channels
09/26/2007EP1163910B1 Rho kinase inhibitors for the prevention or treatment of interstitial pneumonia and pulmonary fibrosis
09/26/2007EP1154998B1 Inhibitors of cellular niacinamide mononucleotide formation and their use in cancer therapy
09/26/2007EP1140960B1 Sulfoalkyl ether cyclodextrin based controlled release solid pharmaceutical formulations
09/26/2007EP1140104B1 Treatment of alzheimer's disease by increasing cytidine levels in vivo
09/26/2007EP1025212B1 Thymidine kinase mutants and fusion proteins having thymidine kinase and guanylate kinase activities
09/26/2007CN101044247A Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
09/26/2007CN101044151A Antiviral 4'-azido-nucleosides
1 ... 3569 3570 3571 3572 3573 3574 3575 3576 3577 3578 3579 3580 3581 3582 3583 3584 3585 3586 3587 3588 3589 ... 7860